Edition:
United Kingdom

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.42USD
13 Aug 2018
Change (% chg)

$-0.01 (-2.07%)
Prev Close
$0.43
Open
$0.43
Day's High
$0.43
Day's Low
$0.41
Volume
174,826
Avg. Vol
652,973
52-wk High
$3.26
52-wk Low
$0.41

Latest Key Developments (Source: Significant Developments)

Celldex Reports Q2 Loss Per Share Of $0.11
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.11.Q2 REVENUE $2.8 MILLION VERSUS I/B/E/S VIEW $2.3 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $114.0 MILLION.  Full Article

Celldex Therapeutics Reports Q1 Loss Per Share $0.84
Thursday, 10 May 2018 

May 10 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.84.Q1 REVENUE $4.1 MILLION VERSUS $1.5 MILLION.Q1 REVENUE VIEW $2.3 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.20 -- THOMSON REUTERS I/B/E/S.CELLDEX - SEES CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AT MAR 31, PROCEEDS FROM SALES OF STOCK SUFFICIENT TO FUND OPERATIONS THROUGH 2020.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $123.2 MILLION VERSUS $139.4 MILLION AS OF DEC 31, 2017.  Full Article

Celldex Therapeutics Approves Workforce Reduction
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Celldex Therapeutics Inc ::CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS.CELLDEX THERAPEUTICS INC - PLANS TO REDUCE ITS 2018 BUDGETED WORKFORCE BY 59 POSITIONS.CELLDEX THERAPEUTICS - REDUCED 2018 BUDGETED WORKFORCE INCLUDES 41 EMPLOYEES TO BE TERMINATED, 18 BUDGETED AND/OR OPEN POSITIONS TO NOT BE FILLED.CELLDEX THERAPEUTICS - EXPECTS TO INCUR RESTRUCTURING CHARGES IN Q2 OF ABOUT $1.3 MILLION RELATED TO CASH SEVERANCE PAYMENTS, OTHER EMPLOYEE-RELATED COSTS.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article

COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016
Friday, 10 Feb 2017 

Columbia Wanger Asset Management LLC:COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING.  Full Article

BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS